<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Market News &#38; Stocks to Watch from StraightStocks &#187; Biotech</title>
	<atom:link href="http://www.straightstocks.com/article/investing-in-biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.straightstocks.com</link>
	<description>Leading Stock Market News, Opinions and Commentary</description>
	<lastBuildDate>Wed, 25 Nov 2009 04:39:17 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Dyax approaching its PDUFA Date (DYAX)</title>
		<link>http://www.straightstocks.com/stock-watch/dyax-approaching-its-pdufa-date-dyax/</link>
		<comments>http://www.straightstocks.com/stock-watch/dyax-approaching-its-pdufa-date-dyax/#comments</comments>
		<pubDate>Tue, 24 Nov 2009 19:41:20 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Angioedema]]></category>
		<category><![CDATA[C1]]></category>
		<category><![CDATA[drug discovery technology;]]></category>
		<category><![CDATA[drug product;]]></category>
		<category><![CDATA[DX-88;]]></category>
		<category><![CDATA[Dyax Corp.]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[FDA Pulmonary]]></category>
		<category><![CDATA[FDA Pulmonary-Allergy Advisory Committee]]></category>
		<category><![CDATA[Gustav A. Christensen]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Hereditary Angioedema]]></category>
		<category><![CDATA[inflammation]]></category>
		<category><![CDATA[INH]]></category>
		<category><![CDATA[inherited disease]]></category>
		<category><![CDATA[life-threatening disease]]></category>
		<category><![CDATA[phage display technology]]></category>
		<category><![CDATA[president and chief executive officer]]></category>
		<category><![CDATA[stage biopharmaceutical;]]></category>
		<category><![CDATA[U.S. Food and Drug  Administration]]></category>
		<category><![CDATA[U.S. Food and Drug Administration]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2178</guid>
		<description><![CDATA[   On 8 June 2009, Dyax Corp. (NASDAQ:DYAX), a clinical stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for inflammatory and oncology diseases, announced that it had obtained from the US Food ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/dyax-approaching-its-pdufa-date-dyax/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Decision scheduled for Santarus (SNTS)</title>
		<link>http://www.straightstocks.com/stock-watch/fda-decision-scheduled-for-santarus-snts/</link>
		<comments>http://www.straightstocks.com/stock-watch/fda-decision-scheduled-for-santarus-snts/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 19:19:25 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Biopharmaceutical]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[diarrhea]]></category>
		<category><![CDATA[DM-1796]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[induction of remission]]></category>
		<category><![CDATA[metformin hydrochloride]]></category>
		<category><![CDATA[Santarus Inc;]]></category>
		<category><![CDATA[sodium bicarbonate;]]></category>
		<category><![CDATA[tablet product]]></category>
		<category><![CDATA[treatment of certain upper GI diseases]]></category>
		<category><![CDATA[ulcerative colitis;]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[www.santarus.com]]></category>
		<category><![CDATA[Zegerid tablet]]></category>
		<category><![CDATA[Zegerid;]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2144</guid>
		<description><![CDATA[   Santarus, Inc. (NASDAQ:SNTS) expects the FDA to decide by December 4, 2009 regarding its NDA for ZEGERID tablet product. A NDA (New Drug Application) for DM-1796 is also expected to be filed with ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/fda-decision-scheduled-for-santarus-snts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Decision scheduled for Santarus (SNTS)</title>
		<link>http://www.straightstocks.com/stock-watch/fda-decision-scheduled-for-santarus-snts/</link>
		<comments>http://www.straightstocks.com/stock-watch/fda-decision-scheduled-for-santarus-snts/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 19:19:25 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Biopharmaceutical]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[diarrhea]]></category>
		<category><![CDATA[DM-1796]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[induction of remission]]></category>
		<category><![CDATA[metformin hydrochloride]]></category>
		<category><![CDATA[Santarus Inc;]]></category>
		<category><![CDATA[sodium bicarbonate;]]></category>
		<category><![CDATA[tablet product]]></category>
		<category><![CDATA[treatment of certain upper GI diseases]]></category>
		<category><![CDATA[ulcerative colitis;]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[www.santarus.com]]></category>
		<category><![CDATA[Zegerid tablet]]></category>
		<category><![CDATA[Zegerid;]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2144</guid>
		<description><![CDATA[   Santarus, Inc. (NASDAQ:SNTS) expects the FDA to decide by December 4, 2009 regarding its NDA for ZEGERID tablet product. A NDA (New Drug Application) for DM-1796 is also expected to be filed with ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/fda-decision-scheduled-for-santarus-snts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CytRx Technical Breakout on Pending News (NASDAQ:CYTR)</title>
		<link>http://www.straightstocks.com/stock-watch/cytrx-technical-breakout-on-pending-news-nasdaqcytr/</link>
		<comments>http://www.straightstocks.com/stock-watch/cytrx-technical-breakout-on-pending-news-nasdaqcytr/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 18:58:25 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2165</guid>
		<description><![CDATA[   Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.14 per share. As of 11/18/09, the ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/cytrx-technical-breakout-on-pending-news-nasdaqcytr/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CytRx Technical Breakout on Pending News (NASDAQ:CYTR)</title>
		<link>http://www.straightstocks.com/stock-watch/cytrx-technical-breakout-on-pending-news-nasdaqcytr-2/</link>
		<comments>http://www.straightstocks.com/stock-watch/cytrx-technical-breakout-on-pending-news-nasdaqcytr-2/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 18:58:25 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Am-80]]></category>
		<category><![CDATA[APL]]></category>
		<category><![CDATA[bone marrow transplant]]></category>
		<category><![CDATA[CytRx Corporation]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[European Medicines Agency]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[MiV Investments Inc.]]></category>
		<category><![CDATA[STAR-1]]></category>
		<category><![CDATA[The star]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2165</guid>
		<description><![CDATA[   Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.35 per share, up 20.18% from ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/cytrx-technical-breakout-on-pending-news-nasdaqcytr-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will the $20 million payment for VIBATIV pay off? (THRX, JNJ, ALPMF)</title>
		<link>http://www.straightstocks.com/stock-watch/will-the-20-million-payment-for-vibativ-pay-off-thrx-jnj-alpmf/</link>
		<comments>http://www.straightstocks.com/stock-watch/will-the-20-million-payment-for-vibativ-pay-off-thrx-jnj-alpmf/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 15:10:24 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2152</guid>
		<description><![CDATA[   The FDA is anticipated to decide on 11/26/09 for Vibativ (telavancin) as a once-daily injectable antibiotic for the treatment of hospital-acquired pneumonia (HAP). This triggers a milestone payment of $10M from THRX&#8217;s partner, ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/will-the-20-million-payment-for-vibativ-pay-off-thrx-jnj-alpmf/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Echo Therapeutics Bullish on Recent News (OTC:ECTE)</title>
		<link>http://www.straightstocks.com/stock-watch/echo-therapeutics-bullish-on-recent-news-otcecte/</link>
		<comments>http://www.straightstocks.com/stock-watch/echo-therapeutics-bullish-on-recent-news-otcecte/#comments</comments>
		<pubDate>Sat, 21 Nov 2009 01:32:00 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[AzoneTS™ Pipeline]]></category>
		<category><![CDATA[comfortable-to-wear continuous glucose monitoring device]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[diabetes care;]]></category>
		<category><![CDATA[drug delivery]]></category>
		<category><![CDATA[Echo Therapeutics Inc.]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[MivInvestments Inc.]]></category>
		<category><![CDATA[Prelude SkinPrep System]]></category>
		<category><![CDATA[skin ablation control technology]]></category>
		<category><![CDATA[Symphony tCGM System]]></category>
		<category><![CDATA[Symphony™ tCGM System]]></category>
		<category><![CDATA[Symphony™ tCGM System Pipeline]]></category>
		<category><![CDATA[transdermal biosensor technologies]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[USD]]></category>
		<category><![CDATA[wireless transmission]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2142</guid>
		<description><![CDATA[   MivInvestments Inc. has initiated an independent bullish technical trading alert for 11/20/09 on Echo Therapeutics, Inc. (OTC:ECTE.OB). Shares of the company finished the day at $1.35, up 8.15% from the opening bell ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/echo-therapeutics-bullish-on-recent-news-otcecte/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ImmunoGen’s Second License to Amgen (IMGN, AMGN)</title>
		<link>http://www.straightstocks.com/stock-watch/immunogen%e2%80%99s-second-license-to-amgen-imgn-amgn/</link>
		<comments>http://www.straightstocks.com/stock-watch/immunogen%e2%80%99s-second-license-to-amgen-imgn-amgn/#comments</comments>
		<pubDate>Fri, 20 Nov 2009 15:45:36 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2115</guid>
		<description><![CDATA[   ImmunoGen, Inc. (NASDAQ:IMGN) has announced that Amgen, Inc. (NASDAQ:AMGN)Inc has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology for the development of anticancer therapeutics to an undisclosed ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/immunogen%e2%80%99s-second-license-to-amgen-imgn-amgn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CombinatoRx  Neuromed Merger at risk? (NASDAQ:CRXX)</title>
		<link>http://www.straightstocks.com/stock-watch/combinatorx-neuromed-merger-at-risk-nasdaqcrxx/</link>
		<comments>http://www.straightstocks.com/stock-watch/combinatorx-neuromed-merger-at-risk-nasdaqcrxx/#comments</comments>
		<pubDate>Fri, 20 Nov 2009 15:30:38 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2121</guid>
		<description><![CDATA[   Neuromed and CombinatoRx, Incorporated (NASDAQ:CRXX)has agreed to sign a definitive merger agreement valued $28.8 million USD on 30th June, 2009 according to a news published by the RTT News.
Although the “merger” declaration with privately ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/combinatorx-neuromed-merger-at-risk-nasdaqcrxx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sucampo Granted Marketing Authorization From FDA (NASDAQ:SCMP)</title>
		<link>http://www.straightstocks.com/stock-watch/sucampo-granted-marketing-authorization-from-fda-nasdaqscmp/</link>
		<comments>http://www.straightstocks.com/stock-watch/sucampo-granted-marketing-authorization-from-fda-nasdaqscmp/#comments</comments>
		<pubDate>Fri, 20 Nov 2009 14:50:33 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2111</guid>
		<description><![CDATA[   Sucampo Pharma Europe Ltd, a subsidiary of Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) has announced that Swissmedic has granted a marketing authorization for Amitiza 24 mcg gel capsules for the long term treatment of ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/sucampo-granted-marketing-authorization-from-fda-nasdaqscmp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Power3 Investors Looking Forward to Expo (OTC:PWRM)</title>
		<link>http://www.straightstocks.com/stock-watch/power3-investors-looking-forward-to-expo-otcpwrm/</link>
		<comments>http://www.straightstocks.com/stock-watch/power3-investors-looking-forward-to-expo-otcpwrm/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 15:23:21 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[ALS]]></category>
		<category><![CDATA[amyotrophic lateral sclerosis]]></category>
		<category><![CDATA[Beijing]]></category>
		<category><![CDATA[Breast Cancer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chair and Keynote Speaker]]></category>
		<category><![CDATA[chief scientific officer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[International Congress]]></category>
		<category><![CDATA[Ira Goldknopf]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[MiV Investments Inc.]]></category>
		<category><![CDATA[neurodegenerative diseases]]></category>
		<category><![CDATA[potential medical applications]]></category>
		<category><![CDATA[Power3 Medical Products Inc.;]]></category>
		<category><![CDATA[Power3;]]></category>
		<category><![CDATA[president]]></category>
		<category><![CDATA[proteomics]]></category>
		<category><![CDATA[treatment of breast cancer]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2106</guid>
		<description><![CDATA[   Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/power3-investors-looking-forward-to-expo-otcpwrm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Power3 Investors Looking Forward to Expo (OTC:PWRM)</title>
		<link>http://www.straightstocks.com/stock-watch/power3-investors-looking-forward-to-expo-otcpwrm/</link>
		<comments>http://www.straightstocks.com/stock-watch/power3-investors-looking-forward-to-expo-otcpwrm/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 15:23:21 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[ALS]]></category>
		<category><![CDATA[amyotrophic lateral sclerosis]]></category>
		<category><![CDATA[Beijing]]></category>
		<category><![CDATA[Breast Cancer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chair and Keynote Speaker]]></category>
		<category><![CDATA[chief scientific officer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[International Congress]]></category>
		<category><![CDATA[Ira Goldknopf]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[MiV Investments Inc.]]></category>
		<category><![CDATA[neurodegenerative diseases]]></category>
		<category><![CDATA[potential medical applications]]></category>
		<category><![CDATA[Power3 Medical Products Inc.;]]></category>
		<category><![CDATA[Power3;]]></category>
		<category><![CDATA[president]]></category>
		<category><![CDATA[proteomics]]></category>
		<category><![CDATA[treatment of breast cancer]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2106</guid>
		<description><![CDATA[   Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/power3-investors-looking-forward-to-expo-otcpwrm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exelixis PI3K Interim Data (NASDAQ:EXEL)</title>
		<link>http://www.straightstocks.com/stock-watch/exelixis-pi3k-interim-data-nasdaqexel/</link>
		<comments>http://www.straightstocks.com/stock-watch/exelixis-pi3k-interim-data-nasdaqexel/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 15:20:25 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2100</guid>
		<description><![CDATA[   Exelixis, Inc (NASDAQ:EXEL) has announced and reported that the interim data from an ongoing Phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/exelixis-pi3k-interim-data-nasdaqexel/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ImmunoGen Announces IMGN901 Data (NASDAQ:IMGN)</title>
		<link>http://www.straightstocks.com/stock-watch/immunogen-announces-imgn901-data-nasdaqimgn/</link>
		<comments>http://www.straightstocks.com/stock-watch/immunogen-announces-imgn901-data-nasdaqimgn/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 15:16:43 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2096</guid>
		<description><![CDATA[   ImmunoGen, Inc (NASDAQ:IMGN) have reported the clinical data of their IMGN901 product candidate which will be used for the treatment of Merkel cell carcinoma (MCC).
The Company mentioned that the meaningful evidence of ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/immunogen-announces-imgn901-data-nasdaqimgn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bullish Technical Breakout Alert (OTC:SNBP)</title>
		<link>http://www.straightstocks.com/stock-watch/bullish-technical-breakout-alert-otcsnbp/</link>
		<comments>http://www.straightstocks.com/stock-watch/bullish-technical-breakout-alert-otcsnbp/#comments</comments>
		<pubDate>Tue, 17 Nov 2009 19:04:21 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2055</guid>
		<description><![CDATA[   Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/17/09 on Sinobiopharma Inc (OTC:SNBP) Inc. has initiated an independent bullish technical trading alert for 11/17/09 on Sinobiopharma, Inc. (OTC:SNBP.OB). Shares of ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/bullish-technical-breakout-alert-otcsnbp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ArQule’s Drug Discovery Platform (NASDAQ:ARQL)</title>
		<link>http://www.straightstocks.com/stock-watch/arqule%e2%80%99s-drug-discovery-platform-nasdaqarql/</link>
		<comments>http://www.straightstocks.com/stock-watch/arqule%e2%80%99s-drug-discovery-platform-nasdaqarql/#comments</comments>
		<pubDate>Tue, 17 Nov 2009 16:00:20 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Arqule Inc;]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Boston]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cancer Therapeutics]]></category>
		<category><![CDATA[Carcinoma]]></category>
		<category><![CDATA[chief scientific officer]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Thomas Chan]]></category>
		<category><![CDATA[tumor]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=2010</guid>
		<description><![CDATA[   ArQule Inc (NASDAQ:ARQL) has presented their data at the AACR-NCI-EORTC meeting in Boston which clearly demonstrates the capabilities of Company’s proprietary drug discovery platform to generate a class of small molecules that ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/arqule%e2%80%99s-drug-discovery-platform-nasdaqarql/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enzo Biochem Ready to Reveal EGS21 Data (NYSE:ENZ)</title>
		<link>http://www.straightstocks.com/stock-watch/enzo-biochem-ready-to-reveal-egs21-data-nyseenz/</link>
		<comments>http://www.straightstocks.com/stock-watch/enzo-biochem-ready-to-reveal-egs21-data-nyseenz/#comments</comments>
		<pubDate>Tue, 17 Nov 2009 15:30:10 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Boston]]></category>
		<category><![CDATA[David Goldberg;]]></category>
		<category><![CDATA[EGS21]]></category>
		<category><![CDATA[Enzo Biochem Inc.]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[insulin resistance;]]></category>
		<category><![CDATA[TA Partnership]]></category>
		<category><![CDATA[Vice President of Corporate Development]]></category>
		<category><![CDATA[Windhover Information Inc]]></category>
		<category><![CDATA[Windhover TA Partnerships]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1998</guid>
		<description><![CDATA[   Enzo Biochem Inc (NYSE:ENZ) has announced that their Vice President of Corporate Development, David Goldberg will speak about Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 Conference which ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/enzo-biochem-ready-to-reveal-egs21-data-nyseenz/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mach One’s Co-Development Plans (OTC:MNCN)</title>
		<link>http://www.straightstocks.com/stock-watch/mach-one%e2%80%99s-co-development-plans-otcmncn/</link>
		<comments>http://www.straightstocks.com/stock-watch/mach-one%e2%80%99s-co-development-plans-otcmncn/#comments</comments>
		<pubDate>Tue, 17 Nov 2009 15:00:13 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1965</guid>
		<description><![CDATA[   Mach One Corporation (OTC:MNCN) has announced that they have completed the first tranche of their investment in PanTheryx, Inc. as stipulated in the recent Letter of Understanding signed in August 2009. This ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/mach-one%e2%80%99s-co-development-plans-otcmncn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Paradigm Medical Industries Exploding. Up 45% (OTC:PDMI)</title>
		<link>http://www.straightstocks.com/stock-watch/paradigm-medical-industries-exploding-up-45-otcpdmi/</link>
		<comments>http://www.straightstocks.com/stock-watch/paradigm-medical-industries-exploding-up-45-otcpdmi/#comments</comments>
		<pubDate>Fri, 13 Nov 2009 15:44:22 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1990</guid>
		<description><![CDATA[   Paradigm Medical Industries, Inc. (OTC:PDMI) is currently breaking out and is up about 45% today on good volume. The stock was consolidating the last few weeks after a 700% gain. Now that the ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/paradigm-medical-industries-exploding-up-45-otcpdmi/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Origin Agritech’s New Facility (NASDAQ:SEED)</title>
		<link>http://www.straightstocks.com/stock-watch/origin-agritech%e2%80%99s-new-facility-nasdaqseed/</link>
		<comments>http://www.straightstocks.com/stock-watch/origin-agritech%e2%80%99s-new-facility-nasdaqseed/#comments</comments>
		<pubDate>Fri, 13 Nov 2009 15:26:56 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1957</guid>
		<description><![CDATA[   Origin Agritech Limited (NASDAQ:SEED) has announced that they have commenced operation of a new hybrid seed drying facility this fall harvest season. This new seed drying facility is operating in the county ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/origin-agritech%e2%80%99s-new-facility-nasdaqseed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PolyMedix Announced Public Offering (OTC:PYMX)</title>
		<link>http://www.straightstocks.com/stock-watch/polymedix-announced-public-offering-otcpymx/</link>
		<comments>http://www.straightstocks.com/stock-watch/polymedix-announced-public-offering-otcpymx/#comments</comments>
		<pubDate>Thu, 12 Nov 2009 18:40:54 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1944</guid>
		<description><![CDATA[   PolyMedix Inc (OTC:PYMX) have announced the pricing of a registered public offering of up to 21,000,000 units consisting of shares and warrants for $1.00 per unit, or a total of up to ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/polymedix-announced-public-offering-otcpymx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vivakor Regeneca Agreement (OTC:VIVK)</title>
		<link>http://www.straightstocks.com/stock-watch/vivakor-regeneca-agreement-otcvivk/</link>
		<comments>http://www.straightstocks.com/stock-watch/vivakor-regeneca-agreement-otcvivk/#comments</comments>
		<pubDate>Thu, 12 Nov 2009 18:37:47 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1948</guid>
		<description><![CDATA[   Vivakor, Inc (OTC:VIVK) announced that they have successfully completed an exclusive distribution agreement with consumer product specialist, Regeneca International, Inc. Vivakor, Inc is a biomedical/biotechnology company with transdisciplinary research that develops and ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/vivakor-regeneca-agreement-otcvivk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Metabolix Prices Public Offering (NASDAQ:MBLX)</title>
		<link>http://www.straightstocks.com/stock-watch/metabolix-prices-public-offering-nasdaqmblx/</link>
		<comments>http://www.straightstocks.com/stock-watch/metabolix-prices-public-offering-nasdaqmblx/#comments</comments>
		<pubDate>Thu, 12 Nov 2009 18:36:57 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1940</guid>
		<description><![CDATA[   Metabolix Inc (NASDAQ:MBLX) have announced that they have priced a public offering of 3.0 million new issued shares of its common stock at a public offering price of US$9.00 per share. The ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/metabolix-prices-public-offering-nasdaqmblx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>IntriCon’s New CDM Device (NASDAQ:IIN)</title>
		<link>http://www.straightstocks.com/stock-watch/intricon%e2%80%99s-new-cdm-device-nasdaqiin/</link>
		<comments>http://www.straightstocks.com/stock-watch/intricon%e2%80%99s-new-cdm-device-nasdaqiin/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 17:30:17 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1912</guid>
		<description><![CDATA[   IntriCon Corporation (NASDAQ:IIN) announced that they will soon unveil a prototype of their new Cardiac Diagnostic Monitoring (CDM) device called the Mobile Patient ECG Telemetry System or MPETS. The Company has announced ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/intricon%e2%80%99s-new-cdm-device-nasdaqiin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OncoVista’s AdnaGen Test (OTC:OVIT)</title>
		<link>http://www.straightstocks.com/stock-watch/oncovista%e2%80%99s-adnagen-test-otcovit/</link>
		<comments>http://www.straightstocks.com/stock-watch/oncovista%e2%80%99s-adnagen-test-otcovit/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 17:00:15 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1909</guid>
		<description><![CDATA[   OncoVista Innovative Therapies, Inc (OTC:OVIT) reported that two of their proprietary products, AdnaTest BreastCancer and AdnaTest ETM1/Stem Cell were being evaluated in Germany by the Department of Gynecology and Obstetrics and Internal ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/oncovista%e2%80%99s-adnagen-test-otcovit/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Depomed Receives Certification Notice (NASDAQ:DEPO)</title>
		<link>http://www.straightstocks.com/stock-watch/depomed-receives-certification-notice-nasdaqdepo/</link>
		<comments>http://www.straightstocks.com/stock-watch/depomed-receives-certification-notice-nasdaqdepo/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 16:30:21 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1916</guid>
		<description><![CDATA[   Depomed, Inc (NASDAQ:DEPO) announced that they have received a Paragraph IV certification notice from Lupin Limited advising Depomed of the filing of an Abbreviated New Drug Application (ANDA) with the Food and ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/depomed-receives-certification-notice-nasdaqdepo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks</title>
		<link>http://www.straightstocks.com/investing-lessons/investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/</link>
		<comments>http://www.straightstocks.com/investing-lessons/investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/#comments</comments>
		<pubDate>Wed, 11 Nov 2009 14:51:32 +0000</pubDate>
		<dc:creator>Investment U</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Contrarian Perspectives]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[InvestmentU]]></category>

		<guid isPermaLink="false">http://www.investmentu.com/IUEL/2009/November/investing-in-the-biotech-sector.html</guid>
		<description><![CDATA[Investing in the Biotech Sector: Here&#8217;s An Easy Way to Profit from Biotech Stocks 
by Marc Lichtenfeld, Healthcare Expert
Wednesday,  November 11, 2009: Issue #1135
Investing in the biotech sector can be risky &#8211; no doubt  about that.
But you know what? There are a lot of ways to make money  from biotech stocks, too. [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/investing-lessons/investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enzon Sigma-Tau Agreement (NASDAQ:ENZN)</title>
		<link>http://www.straightstocks.com/stock-watch/enzon-sigma-tau-agreement-nasdaqenzn/</link>
		<comments>http://www.straightstocks.com/stock-watch/enzon-sigma-tau-agreement-nasdaqenzn/#comments</comments>
		<pubDate>Tue, 10 Nov 2009 15:00:06 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1891</guid>
		<description><![CDATA[Enzon Pharmaceuticals, Inc (NASDAQ:ENZN) has announced that they have entered into a definitive agreement to sell their specialty pharmaceutical business to Sigma-Tau Group for US$300 million along with milestone payments of US$27 million. Additionally, Enzon ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/enzon-sigma-tau-agreement-nasdaqenzn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ziopharm Shows Positive Results (NASDAQ:ZIOP)</title>
		<link>http://www.straightstocks.com/stock-watch/ziopharm-shows-positive-results-nasdaqziop/</link>
		<comments>http://www.straightstocks.com/stock-watch/ziopharm-shows-positive-results-nasdaqziop/#comments</comments>
		<pubDate>Mon, 09 Nov 2009 18:05:30 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1848</guid>
		<description><![CDATA[Ziopharm Oncology, Inc. (NASDAQ:ZIOP) has announced today and presented their positive interim data from the multicenter randomized Phase 2 trial of Palifosfamide also known as Zymafos that will be used for the treating patients with ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/ziopharm-shows-positive-results-nasdaqziop/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PPD Acquires Excel PharmaStudies (NASDAQ:PPDI)</title>
		<link>http://www.straightstocks.com/stock-watch/ppd-acquires-excel-pharmastudies-nasdaqppdi/</link>
		<comments>http://www.straightstocks.com/stock-watch/ppd-acquires-excel-pharmastudies-nasdaqppdi/#comments</comments>
		<pubDate>Mon, 09 Nov 2009 18:05:16 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1852</guid>
		<description><![CDATA[PPD or Pharmaceutical Product Development, Inc (NASDAQ:PPDI) today announced that they have completed their acquisition of Excel PharmaStudies Inc which is considered to be the market leader and one of the largest contract research organizations ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/ppd-acquires-excel-pharmastudies-nasdaqppdi/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>QuantRx’s Diagnostic Reader (OTC:QTXB)</title>
		<link>http://www.straightstocks.com/stock-watch/quantrx%e2%80%99s-diagnostic-reader-otcqtxb/</link>
		<comments>http://www.straightstocks.com/stock-watch/quantrx%e2%80%99s-diagnostic-reader-otcqtxb/#comments</comments>
		<pubDate>Mon, 09 Nov 2009 18:05:00 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1856</guid>
		<description><![CDATA[QuantRx Biomedical Corporation (OTC:QTXB) has announced that the Company will soon demonstrate its latest technology at the MEDICA 2009. The Company announced that QuantRx has developed a new point-of-care medical device that will introduce for ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/quantrx%e2%80%99s-diagnostic-reader-otcqtxb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NovaDel’s USPTO Allowance Notice (AMEX:NVD)</title>
		<link>http://www.straightstocks.com/stock-watch/novadel%e2%80%99s-uspto-allowance-notice-amexnvd/</link>
		<comments>http://www.straightstocks.com/stock-watch/novadel%e2%80%99s-uspto-allowance-notice-amexnvd/#comments</comments>
		<pubDate>Fri, 06 Nov 2009 16:00:08 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1834</guid>
		<description><![CDATA[NovaDel Pharma Inc. (AMEX:NVD) announced that they have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715 entitled “Buccal, Polar and Non-Polar ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/novadel%e2%80%99s-uspto-allowance-notice-amexnvd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Entest Biomedical COPD Treatments (OTC:ENTB)</title>
		<link>http://www.straightstocks.com/stock-watch/entest-biomedical-copd-treatments-otcentb/</link>
		<comments>http://www.straightstocks.com/stock-watch/entest-biomedical-copd-treatments-otcentb/#comments</comments>
		<pubDate>Fri, 06 Nov 2009 15:45:06 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1830</guid>
		<description><![CDATA[Entest Biomedical Inc (OTC:ENTB) announced that the Company’s unique treatments for Chronic Obstructive Pulmonary Disease also known as COPD, which is currently under development, can lead to substantial revenue opportunities in the near future. Entest ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/entest-biomedical-copd-treatments-otcentb/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ligand Pfizer Collaboration Extended (NASDAQ:LGND)</title>
		<link>http://www.straightstocks.com/stock-watch/ligand-pfizer-collaboration-extended-nasdaqlgnd/</link>
		<comments>http://www.straightstocks.com/stock-watch/ligand-pfizer-collaboration-extended-nasdaqlgnd/#comments</comments>
		<pubDate>Fri, 06 Nov 2009 15:30:04 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1826</guid>
		<description><![CDATA[Ligand Pharmaceuticals Inc (NASDAQ:LGND) has announced that they have extended their research collaboration with Pfizer for JAK3 by one year. Both the companies had entered the research and license agreement in December 2006 with Wyeth ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/ligand-pfizer-collaboration-extended-nasdaqlgnd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dendreon Corp. (Nasdaq: DNDN): Put These Two Promising Biotech Stocks on Your Watch List</title>
		<link>http://www.straightstocks.com/investing-lessons/dendreon-corp-nasdaq-dndn-put-these-two-promising-biotech-stocks-on-your-watch-list/</link>
		<comments>http://www.straightstocks.com/investing-lessons/dendreon-corp-nasdaq-dndn-put-these-two-promising-biotech-stocks-on-your-watch-list/#comments</comments>
		<pubDate>Fri, 06 Nov 2009 14:08:25 +0000</pubDate>
		<dc:creator>Investment U</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Contrarian Perspectives]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[InvestmentU]]></category>

		<guid isPermaLink="false">http://www.investmentu.com/IUEL/2009/November/dendreon-corp.html</guid>
		<description><![CDATA[Put These Two Promising Biotech Stocks on Your Watch List
by Louis Basenese, Small Cap and Special Situations Expert
Friday, November 6, 2009: Issue #1132
All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN),  this year is well deserved.
After all, the market potential for its prostate cancer  treatment, Provenge, is significant. This year, 190,000 [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/investing-lessons/dendreon-corp-nasdaq-dndn-put-these-two-promising-biotech-stocks-on-your-watch-list/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pro-Pharmaceuticals Private Placement (OTC:PRWP)</title>
		<link>http://www.straightstocks.com/stock-watch/pro-pharmaceuticals-private-placement-otcprwp/</link>
		<comments>http://www.straightstocks.com/stock-watch/pro-pharmaceuticals-private-placement-otcprwp/#comments</comments>
		<pubDate>Thu, 05 Nov 2009 16:45:00 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1811</guid>
		<description><![CDATA[Pro-Pharmaceuticals, Inc. (OTC:PRWP) has announced that they have closed a US$310,000 tranche of a private placement for up to US$6.0 million with 10X Fund, L.P. which is purchasing their unregistered Series B convertible preferred stocks ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/pro-pharmaceuticals-private-placement-otcprwp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MabCure Signs Research Agreement (OTC:MBCI)</title>
		<link>http://www.straightstocks.com/stock-watch/mabcure-signs-research-agreement-otcmbci/</link>
		<comments>http://www.straightstocks.com/stock-watch/mabcure-signs-research-agreement-otcmbci/#comments</comments>
		<pubDate>Thu, 05 Nov 2009 16:16:58 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1807</guid>
		<description><![CDATA[MabCure N.V., a subsidiary of MabCure Inc (OTC:MBCI) today announced that they have signed a research agreement with AZ Sint Lucas Hospital in Belgium to conduct preclinical research on its monoclonal antibodies against different cancers. ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/mabcure-signs-research-agreement-otcmbci/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enzo Biochem at Bio-Europe 2009 (NYSE:ENZ)</title>
		<link>http://www.straightstocks.com/stock-watch/enzo-biochem-at-bio-europe-2009-nyseenz/</link>
		<comments>http://www.straightstocks.com/stock-watch/enzo-biochem-at-bio-europe-2009-nyseenz/#comments</comments>
		<pubDate>Thu, 05 Nov 2009 16:00:56 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1803</guid>
		<description><![CDATA[Speaking at the Bio-Europe 2009 Conference in Austria, Enzo Biochem, Inc (NYSE:ENZ) announced that the Company’s therapeutic platforms are utilizing oral immune regulation for immune mediated diseases. The Company further said that the oral immune ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/enzo-biochem-at-bio-europe-2009-nyseenz/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covidien and Nuvo Research FDA action date set for today (NYSE:COV, PINK:NRIFF)</title>
		<link>http://www.straightstocks.com/stock-watch/covidien-and-nuvo-research-fda-action-date-set-for-today-nysecov-pinknriff/</link>
		<comments>http://www.straightstocks.com/stock-watch/covidien-and-nuvo-research-fda-action-date-set-for-today-nysecov-pinknriff/#comments</comments>
		<pubDate>Wed, 04 Nov 2009 19:21:21 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1792</guid>
		<description><![CDATA[Covidien (NYSE: COV), a leading global provider of healthcare products, and Nuvo Research Inc. (PINK: NRIFF), a Canadian drug development company, both have an action date of today 11/4/2009 from the Food and Drug Administration ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/covidien-and-nuvo-research-fda-action-date-set-for-today-nysecov-pinknriff/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Omnicare Finalized Settlement Agreement (NYSE:OCR)</title>
		<link>http://www.straightstocks.com/stock-watch/omnicare-finalized-settlement-agreement-nyseocr/</link>
		<comments>http://www.straightstocks.com/stock-watch/omnicare-finalized-settlement-agreement-nyseocr/#comments</comments>
		<pubDate>Wed, 04 Nov 2009 14:00:45 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1774</guid>
		<description><![CDATA[Omnicare, Inc. (NYSE:OCR) have announced today that they have gone ahead and finalized the previously disclosed agreement for a voluntary civil settlement with the US Attorney’s Office, District of Massachusetts, the Department of Justice and ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/omnicare-finalized-settlement-agreement-nyseocr/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UNDT’s Black Mold Detection (OTC:UNDT)</title>
		<link>http://www.straightstocks.com/stock-watch/undt%e2%80%99s-black-mold-detection-otcundt/</link>
		<comments>http://www.straightstocks.com/stock-watch/undt%e2%80%99s-black-mold-detection-otcundt/#comments</comments>
		<pubDate>Wed, 04 Nov 2009 12:30:43 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1768</guid>
		<description><![CDATA[Universal Detection Technology (OTC:UNDT) has announced that they are expanding their product catalogue which will now include a consumer ready kit for the detection of black mold. The Company has been a developer of early ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/undt%e2%80%99s-black-mold-detection-otcundt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>RXi’s Therapeutic Platform (NASDAQ:RXII)</title>
		<link>http://www.straightstocks.com/stock-watch/rxi%e2%80%99s-therapeutic-platform-nasdaqrxii/</link>
		<comments>http://www.straightstocks.com/stock-watch/rxi%e2%80%99s-therapeutic-platform-nasdaqrxii/#comments</comments>
		<pubDate>Wed, 04 Nov 2009 12:00:40 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1763</guid>
		<description><![CDATA[RXi Pharmaceuticals Corporation (NASDAQ:RXII) announced that their Vice President of Technology Development, Dmitry Samarsky will be presenting their new RNAi technology development at the Discovery on Target scientific conference in Boston on November 4, 2009. ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/rxi%e2%80%99s-therapeutic-platform-nasdaqrxii/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gilead Sciences Combination Therapy (NASDAQ:GILD)</title>
		<link>http://www.straightstocks.com/stock-watch/gilead-sciences-combination-therapy-nasdaqgild/</link>
		<comments>http://www.straightstocks.com/stock-watch/gilead-sciences-combination-therapy-nasdaqgild/#comments</comments>
		<pubDate>Tue, 03 Nov 2009 15:45:42 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1746</guid>
		<description><![CDATA[Gilead Sciences, Inc. (NASDAQ:GILD) in partnership with the GlaxoSmithKline plc (ADR) (NYSE:GSK) today has announced their plans for an international clinical trial to study the combination therapy versus monotherapy in a first-line treatment setting for pulmonary ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/gilead-sciences-combination-therapy-nasdaqgild/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ariad’s AP24534 in Publication (NASDAQ:ARIA)</title>
		<link>http://www.straightstocks.com/stock-watch/ariad%e2%80%99s-ap24534-in-publication-nasdaqaria/</link>
		<comments>http://www.straightstocks.com/stock-watch/ariad%e2%80%99s-ap24534-in-publication-nasdaqaria/#comments</comments>
		<pubDate>Tue, 03 Nov 2009 15:20:40 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1742</guid>
		<description><![CDATA[Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that Cancer Cell, one of the leading scientific journals, has published a comprehensive paper describing the design and preclinical characterization of an investigational kinase inhibitor (AP24534). The paper mentions ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/ariad%e2%80%99s-ap24534-in-publication-nasdaqaria/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enzo Biochem NASH Results (NYSE:ENZ)</title>
		<link>http://www.straightstocks.com/stock-watch/enzo-biochem-nash-results-nyseenz/</link>
		<comments>http://www.straightstocks.com/stock-watch/enzo-biochem-nash-results-nyseenz/#comments</comments>
		<pubDate>Tue, 03 Nov 2009 15:00:35 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[+Metabolic Syndrome]]></category>
		<category><![CDATA[American Association for the Study of Liver Diseases]]></category>
		<category><![CDATA[Biopharmaceuticals]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Enzo]]></category>
		<category><![CDATA[Enzo Biochem Inc.]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[genetic engineering]]></category>
		<category><![CDATA[healthcare products]]></category>
		<category><![CDATA[insulin resistance;]]></category>
		<category><![CDATA[liver diseases;]]></category>
		<category><![CDATA[obesity]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1737</guid>
		<description><![CDATA[Enzo Biochem Inc. (NYSE:ENZ) announced today that they have favorable results of the Company’s clinical trial for the treatment of non-alcoholic steatohepatitis. The information was presented by Enzo Biochem at the annual meeting of the ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/enzo-biochem-nash-results-nyseenz/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rosetta Genomics’ Diagnostic Program Update (NASDAQ:ROSG)</title>
		<link>http://www.straightstocks.com/stock-watch/rosetta-genomics%e2%80%99-diagnostic-program-update-nasdaqrosg/</link>
		<comments>http://www.straightstocks.com/stock-watch/rosetta-genomics%e2%80%99-diagnostic-program-update-nasdaqrosg/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 20:37:50 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Ayelet Chajut]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cancers]]></category>
		<category><![CDATA[Colon Cancer]]></category>
		<category><![CDATA[early detection cancer screening products]]></category>
		<category><![CDATA[Executive Vice President]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[final product]]></category>
		<category><![CDATA[head]]></category>
		<category><![CDATA[molecular biology ;]]></category>
		<category><![CDATA[molecular diagnostic]]></category>
		<category><![CDATA[molecular diagnostic products]]></category>
		<category><![CDATA[Philadelphia]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Rosetta Genomics]]></category>
		<category><![CDATA[Vice President]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1722</guid>
		<description><![CDATA[Rosetta Genomics (NASDAQ:ROSG) today announced an update regarding their colon cancer diagnostic program and said that Ayelet Chajut, Executive Vice President, R&#38;D, Head of Molecular Biology will speak more about this program at the 6th ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/rosetta-genomics%e2%80%99-diagnostic-program-update-nasdaqrosg/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Geron Will Re-initiate Clinical Trials (NASDAQ:GERN)</title>
		<link>http://www.straightstocks.com/stock-watch/geron-will-re-initiate-clinical-trials-nasdaqgern/</link>
		<comments>http://www.straightstocks.com/stock-watch/geron-will-re-initiate-clinical-trials-nasdaqgern/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 20:22:38 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Biopharmaceuticals]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical injuries]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Drug Candidate]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Geron Corporation;]]></category>
		<category><![CDATA[GRNOPC1;]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Multiple Sclerosis]]></category>
		<category><![CDATA[same drug candidate]]></category>
		<category><![CDATA[spinal cord injuries]]></category>
		<category><![CDATA[Spinal Cord Injury]]></category>
		<category><![CDATA[stroke]]></category>
		<category><![CDATA[thoracic injuries]]></category>
		<category><![CDATA[Treatment Of Cancer]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1713</guid>
		<description><![CDATA[Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury. The company said that they plan to advance clinical development ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/geron-will-re-initiate-clinical-trials-nasdaqgern/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BSD Medical’s Hyperthermia Therapy (NASDAQ:BSDM)</title>
		<link>http://www.straightstocks.com/stock-watch/bsd-medical%e2%80%99s-hyperthermia-therapy-nasdaqbsdm/</link>
		<comments>http://www.straightstocks.com/stock-watch/bsd-medical%e2%80%99s-hyperthermia-therapy-nasdaqbsdm/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 19:25:49 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Bladder Cancer]]></category>
		<category><![CDATA[bladder tumors]]></category>
		<category><![CDATA[BSD Medical Corporation]]></category>
		<category><![CDATA[European Society for Therapeutic Radiology and Oncology]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[thermal treatment systems]]></category>
		<category><![CDATA[tumor]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[University of Erlangen]]></category>
		<category><![CDATA[University of Frankfurt and Hospital Martha-Maria in Germany]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1718</guid>
		<description><![CDATA[BSD Medical Corporation (NASDAQ:BSDM) today announced that their published study results demonstrated improvement in the overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy delivered through BSD-2000 Hyperthermia System. ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/bsd-medical%e2%80%99s-hyperthermia-therapy-nasdaqbsdm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Depomed Q3 Financial Results (NASDAQ:DEPO)</title>
		<link>http://www.straightstocks.com/stock-watch/depomed-q3-financial-results-nasdaqdepo/</link>
		<comments>http://www.straightstocks.com/stock-watch/depomed-q3-financial-results-nasdaqdepo/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 14:33:04 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[DM-1796]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Glumetza]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Merck & Co. Inc.]]></category>
		<category><![CDATA[metformin hydrochloride]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[postherpetic neuralgia;]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1691</guid>
		<description><![CDATA[Depomed, Inc (NASDAQ:DEPO) today reported financial results for the third quarter that ended on September 30, 2009. The revenue for the three months ended September 30, 2009 was US$23 million compared to US$14.1 million for ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/depomed-q3-financial-results-nasdaqdepo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dynavax with new HEPLISAV Data (NASDAQ:DVAX)</title>
		<link>http://www.straightstocks.com/stock-watch/dynavax-with-new-heplisav-data-nasdaqdvax/</link>
		<comments>http://www.straightstocks.com/stock-watch/dynavax-with-new-heplisav-data-nasdaqdvax/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 14:15:40 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Biopharmaceutical]]></category>
		<category><![CDATA[chronic kidney disease;]]></category>
		<category><![CDATA[Dynavax Technologies Corporation]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Hepatitis B;]]></category>
		<category><![CDATA[Infectious Disease Society of America]]></category>
		<category><![CDATA[Pennsylvania]]></category>
		<category><![CDATA[Philadelphia]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[viral infection]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1687</guid>
		<description><![CDATA[In one of the most surprising news today, Dynavax Technologies Corporation (NASDAQ:DVAX) has announced that the first clinical data of their HEPLISAV has shown increase in the protection rate for chronic kidney disease patients. The data ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/dynavax-with-new-heplisav-data-nasdaqdvax/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Celera and Medical Therapies (NASDAQ:CRA)</title>
		<link>http://www.straightstocks.com/stock-watch/celera-and-medical-therapies-nasdaqcra/</link>
		<comments>http://www.straightstocks.com/stock-watch/celera-and-medical-therapies-nasdaqcra/#comments</comments>
		<pubDate>Fri, 30 Oct 2009 14:00:42 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Berkeley HeartLab Inc]]></category>
		<category><![CDATA[Biopharmaceutical]]></category>
		<category><![CDATA[Celera Corporation;]]></category>
		<category><![CDATA[clinical laboratory testing services;]]></category>
		<category><![CDATA[corporate management;]]></category>
		<category><![CDATA[Diagnostic Products]]></category>
		<category><![CDATA[disease management services]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[Lung Cancer]]></category>
		<category><![CDATA[Medical Therapies Limited]]></category>
		<category><![CDATA[personalized disease]]></category>
		<category><![CDATA[personalized disease management products]]></category>
		<category><![CDATA[small cell lung cancer]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1682</guid>
		<description><![CDATA[On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/celera-and-medical-therapies-nasdaqcra/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bioelectronics Answers Shareholder Questions (OTC:BIEL)</title>
		<link>http://www.straightstocks.com/stock-watch/bioelectronics-answers-shareholder-questions-otcbiel/</link>
		<comments>http://www.straightstocks.com/stock-watch/bioelectronics-answers-shareholder-questions-otcbiel/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 16:44:12 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1670</guid>
		<description><![CDATA[Bioelectronics Corp (OTC:BIEL) answered many shareholder questions in a email from Joe Noel posted by MarselusWallace. These questions and answers from Joe Noel are not modified in any way and contains numerous typos as these ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/bioelectronics-answers-shareholder-questions-otcbiel/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CytRx’s Seeking Destruction Of Cancer Cells (NASDAQ:CYTR)</title>
		<link>http://www.straightstocks.com/stock-watch/cytrx%e2%80%99s-seeking-destruction-of-cancer-cells-nasdaqcytr/</link>
		<comments>http://www.straightstocks.com/stock-watch/cytrx%e2%80%99s-seeking-destruction-of-cancer-cells-nasdaqcytr/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 16:38:40 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Acute Promyelocytic Leukemia]]></category>
		<category><![CDATA[ALS]]></category>
		<category><![CDATA[anti-aging pharmaceuticals]]></category>
		<category><![CDATA[APL]]></category>
		<category><![CDATA[Beth Israel]]></category>
		<category><![CDATA[Beth Israel Deaconess Medical Center]]></category>
		<category><![CDATA[biopharmaceutical research]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CytRx Corporation]]></category>
		<category><![CDATA[drug development]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Harvard Medical School;]]></category>
		<category><![CDATA[molecular chaperone technology]]></category>
		<category><![CDATA[neurodegenerative disease;]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[revised protocol]]></category>
		<category><![CDATA[stroke]]></category>
		<category><![CDATA[Stuart K. Calderwood]]></category>
		<category><![CDATA[treatment of acute promyelocytic leukemia]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1666</guid>
		<description><![CDATA[CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future. CytRx Corporation is ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/cytrx%e2%80%99s-seeking-destruction-of-cancer-cells-nasdaqcytr/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Columbia Laboratories Registered Direct Offering (NASDAQ:CBRX)</title>
		<link>http://www.straightstocks.com/stock-watch/columbia-laboratories-registered-direct-offering-nasdaqcbrx/</link>
		<comments>http://www.straightstocks.com/stock-watch/columbia-laboratories-registered-direct-offering-nasdaqcbrx/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 16:27:20 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Columbia Laboratories]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[general corporate purposes]]></category>
		<category><![CDATA[progesterone products]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1661</guid>
		<description><![CDATA[Columbia Laboratories, Inc. (NASDAQ:CBRX), a company that is into the development, manufacturing and commercialization of pharmaceutical products has successfully raised around $11,772,000 in gross proceeds through the sale of 10,900,000 shares of its common stock ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/columbia-laboratories-registered-direct-offering-nasdaqcbrx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Celera’s New Agreement With Laboratory Service (NASDAQ:CRA)</title>
		<link>http://www.straightstocks.com/stock-watch/celera%e2%80%99s-new-agreement-with-laboratory-service-nasdaqcra/</link>
		<comments>http://www.straightstocks.com/stock-watch/celera%e2%80%99s-new-agreement-with-laboratory-service-nasdaqcra/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 16:23:44 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Allergy]]></category>
		<category><![CDATA[Berkeley HeartLab;]]></category>
		<category><![CDATA[biochemical]]></category>
		<category><![CDATA[cardiovascular disease]]></category>
		<category><![CDATA[Celera Corporation;]]></category>
		<category><![CDATA[clinical laboratory services]]></category>
		<category><![CDATA[disease management]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Geisinger Medical Center]]></category>
		<category><![CDATA[healthcare business focusing]]></category>
		<category><![CDATA[hematology testing]]></category>
		<category><![CDATA[microbiology]]></category>
		<category><![CDATA[patient management]]></category>
		<category><![CDATA[Proven Diagnostics]]></category>
		<category><![CDATA[selected diagnostic tools]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1653</guid>
		<description><![CDATA[Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/celera%e2%80%99s-new-agreement-with-laboratory-service-nasdaqcra/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Columbia Laboratories Completes Registered Direct Offering (NASDAQ:CBRX)</title>
		<link>http://www.straightstocks.com/stock-watch/columbia-laboratories-completes-registered-direct-offering-nasdaqcbrx/</link>
		<comments>http://www.straightstocks.com/stock-watch/columbia-laboratories-completes-registered-direct-offering-nasdaqcbrx/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 14:00:45 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Columbia Laboratories]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[general corporate purposes]]></category>
		<category><![CDATA[progesterone products]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1591</guid>
		<description><![CDATA[Columbia Laboratories, Inc. (NASDAQ:CBRX), a company that is into the development, manufacturing and commercialization of pharmaceutical products has successfully raised around $11,772,000 in gross proceeds through the sale of 10,900,000 shares of its common stock ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/columbia-laboratories-completes-registered-direct-offering-nasdaqcbrx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CytRx’s Selective Destruction Of Cancer Cells (NASDAQ:CYTR)</title>
		<link>http://www.straightstocks.com/stock-watch/cytrx%e2%80%99s-selective-destruction-of-cancer-cells-nasdaqcytr/</link>
		<comments>http://www.straightstocks.com/stock-watch/cytrx%e2%80%99s-selective-destruction-of-cancer-cells-nasdaqcytr/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 13:45:40 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Acute Promyelocytic Leukemia]]></category>
		<category><![CDATA[ALS]]></category>
		<category><![CDATA[anti-aging pharmaceuticals]]></category>
		<category><![CDATA[APL]]></category>
		<category><![CDATA[Beth Israel]]></category>
		<category><![CDATA[Beth Israel Deaconess Medical Center]]></category>
		<category><![CDATA[biopharmaceutical research]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CytRx Corporation]]></category>
		<category><![CDATA[drug development]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Harvard Medical School;]]></category>
		<category><![CDATA[molecular chaperone technology]]></category>
		<category><![CDATA[neurodegenerative disease;]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[revised protocol]]></category>
		<category><![CDATA[stroke]]></category>
		<category><![CDATA[Stuart K. Calderwood]]></category>
		<category><![CDATA[treatment of acute promyelocytic leukemia]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1583</guid>
		<description><![CDATA[CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future. CytRx Corporation is ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/cytrx%e2%80%99s-selective-destruction-of-cancer-cells-nasdaqcytr/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bioelectronics Answers Key Shareholder Questions (OTC:BIEL)</title>
		<link>http://www.straightstocks.com/stock-watch/bioelectronics-answers-key-shareholder-questions-otcbiel/</link>
		<comments>http://www.straightstocks.com/stock-watch/bioelectronics-answers-key-shareholder-questions-otcbiel/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 13:30:25 +0000</pubDate>
		<dc:creator>Jay Garcilazo</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[BioElectronics Corp.]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[Joe Noel]]></category>
		<category><![CDATA[official sales figures]]></category>
		<category><![CDATA[speech dictation software]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1595</guid>
		<description><![CDATA[Bioelectronics Corp (OTC:BIEL) answered many shareholder questions in a email from Joe Noel posted by MarselusWallace. These questions and answers from Joe Noel are not modified in any way and contains numerous typos as these ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/bioelectronics-answers-key-shareholder-questions-otcbiel/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Celera Agreement With Clinical Laboratory Service (NASDAQ:CRA)</title>
		<link>http://www.straightstocks.com/stock-watch/celera-agreement-with-clinical-laboratory-service-nasdaqcra/</link>
		<comments>http://www.straightstocks.com/stock-watch/celera-agreement-with-clinical-laboratory-service-nasdaqcra/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 13:15:43 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Allergy]]></category>
		<category><![CDATA[Berkeley HeartLab;]]></category>
		<category><![CDATA[biochemical]]></category>
		<category><![CDATA[cardiovascular disease]]></category>
		<category><![CDATA[Celera Corporation;]]></category>
		<category><![CDATA[clinical laboratory services]]></category>
		<category><![CDATA[disease management]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Geisinger Medical Center]]></category>
		<category><![CDATA[healthcare business focusing]]></category>
		<category><![CDATA[hematology testing]]></category>
		<category><![CDATA[microbiology]]></category>
		<category><![CDATA[patient management]]></category>
		<category><![CDATA[Proven Diagnostics]]></category>
		<category><![CDATA[selected diagnostic tools]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1587</guid>
		<description><![CDATA[Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/celera-agreement-with-clinical-laboratory-service-nasdaqcra/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Theravance’s New Horizon (THRX, GSK)</title>
		<link>http://www.straightstocks.com/stock-watch/theravance%e2%80%99s-new-horizon-thrx-gsk/</link>
		<comments>http://www.straightstocks.com/stock-watch/theravance%e2%80%99s-new-horizon-thrx-gsk/#comments</comments>
		<pubDate>Wed, 28 Oct 2009 14:00:05 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1563</guid>
		<description><![CDATA[Theravance, Inc. (NASDAQ:THRX) today announced that they have commence Phase 3 of Horizon programme with GlaxoSmithKline plc (ADR) (NYSE:GSK) to develop a next generation treatment for COPD. All patients within the Horizon programme will be dosed ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/theravance%e2%80%99s-new-horizon-thrx-gsk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ZymoGenetics receives milestone payment</title>
		<link>http://www.straightstocks.com/stock-watch/zymogenetics-receives-milestone-payment/</link>
		<comments>http://www.straightstocks.com/stock-watch/zymogenetics-receives-milestone-payment/#comments</comments>
		<pubDate>Wed, 28 Oct 2009 13:50:02 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1559</guid>
		<description><![CDATA[ZymoGenetics, Inc. (NASDAQ:ZGEN) announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment naive patients with chronic hepatitis C virus (HCV) infection. Hence the Seattle-based ZymoGenetics will receive ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/zymogenetics-receives-milestone-payment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arena Pharmaceuticals New Data (NASDAQ:ARNA)</title>
		<link>http://www.straightstocks.com/stock-watch/arena-pharmaceuticals-new-data-nasdaqarna/</link>
		<comments>http://www.straightstocks.com/stock-watch/arena-pharmaceuticals-new-data-nasdaqarna/#comments</comments>
		<pubDate>Wed, 28 Oct 2009 13:40:58 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1555</guid>
		<description><![CDATA[Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced new findings today, adding to the previously announced top line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in about four thousand patients. ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/arena-pharmaceuticals-new-data-nasdaqarna/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Orexigen’s New Data (NASDAQ:OREX)</title>
		<link>http://www.straightstocks.com/stock-watch/orexigen%e2%80%99s-new-data-nasdaqorex/</link>
		<comments>http://www.straightstocks.com/stock-watch/orexigen%e2%80%99s-new-data-nasdaqorex/#comments</comments>
		<pubDate>Wed, 28 Oct 2009 13:30:57 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Biopharmaceutical]]></category>
		<category><![CDATA[cardiovascular disease]]></category>
		<category><![CDATA[Contrave]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[food cravings]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[Obesity Society]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.;]]></category>
		<category><![CDATA[pharmaceutical product candidates]]></category>
		<category><![CDATA[treatment of obesity]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1551</guid>
		<description><![CDATA[Orexigen Therapeutics, Inc. (NASDAQ:OREX) has announced and presented their new data from the COR diabetes trials for Contrave to expand on top line results announced in July this year. This new data shows that after ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/orexigen%e2%80%99s-new-data-nasdaqorex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GSK Arzerra Approved (NYSE:GSK)</title>
		<link>http://www.straightstocks.com/stock-watch/gsk-arzerra-approved-nysegsk/</link>
		<comments>http://www.straightstocks.com/stock-watch/gsk-arzerra-approved-nysegsk/#comments</comments>
		<pubDate>Tue, 27 Oct 2009 17:40:49 +0000</pubDate>
		<dc:creator>Mike Brown</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[antibodies]]></category>
		<category><![CDATA[Biopharmaceutical]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[chronic lymphocytic leukemia]]></category>
		<category><![CDATA[consumer products]]></category>
		<category><![CDATA[Denmark]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Genmab A/S;]]></category>
		<category><![CDATA[Glaxosmithkline Plc]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[Leukemia Treatment]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[oncology products;]]></category>
		<category><![CDATA[Pharmaceutical Products]]></category>
		<category><![CDATA[treatment of life-threatening and dangerous diseases]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1518</guid>
		<description><![CDATA[On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/gsk-arzerra-approved-nysegsk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi drags Hospira and Apotex (NYSE:SNY)</title>
		<link>http://www.straightstocks.com/stock-watch/sanofi-drags-hospira-and-apotex-nysesny/</link>
		<comments>http://www.straightstocks.com/stock-watch/sanofi-drags-hospira-and-apotex-nysesny/#comments</comments>
		<pubDate>Tue, 27 Oct 2009 16:54:31 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Apotex Inc]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapies]]></category>
		<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Delaware]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[head cancers]]></category>
		<category><![CDATA[healthcare products]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[liver head]]></category>
		<category><![CDATA[metabolic disorders;]]></category>
		<category><![CDATA[neck cancers]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[Pharmaceutical Group]]></category>
		<category><![CDATA[Sanofi-Aventis S.A.]]></category>
		<category><![CDATA[skilled chemist]]></category>
		<category><![CDATA[small cell lung cancer]]></category>
		<category><![CDATA[Taxotere]]></category>
		<category><![CDATA[thrombosis]]></category>
		<category><![CDATA[Treatment Of Cancer]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1525</guid>
		<description><![CDATA[Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere. Sanofi-Aventis has said that both the companies have tried to copy ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/sanofi-drags-hospira-and-apotex-nysesny/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lifeline Estimates Six Months For FDA Response (PINK:LLBO)</title>
		<link>http://www.straightstocks.com/stock-watch/lifeline-estimates-six-months-for-fda-response-pinkllbo/</link>
		<comments>http://www.straightstocks.com/stock-watch/lifeline-estimates-six-months-for-fda-response-pinkllbo/#comments</comments>
		<pubDate>Mon, 26 Oct 2009 19:54:44 +0000</pubDate>
		<dc:creator>Mike Brown</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1504</guid>
		<description><![CDATA[Lifeline Biotech (Public, PINK:LLBO) reported today about the status of their First Warning System™ 510(k) FDA application. The consulting firm, Lifeline Biotech used to submit the FDA application, advised that the &#8220;FDA is running anywhere from ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/lifeline-estimates-six-months-for-fda-response-pinkllbo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novo Nordisk races ahead (NYSE:NVO)</title>
		<link>http://www.straightstocks.com/stock-watch/novo-nordisk-races-ahead-nysenvo/</link>
		<comments>http://www.straightstocks.com/stock-watch/novo-nordisk-races-ahead-nysenvo/#comments</comments>
		<pubDate>Mon, 26 Oct 2009 14:30:44 +0000</pubDate>
		<dc:creator>Sandra Kitchen</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1485</guid>
		<description><![CDATA[Novo Nordisk A/S (ADR) (NYSE:NVO) has made an announcement that their diabetes treatment Liraglutide cuts weight and reduces health risks in obese non-diabetics. The Denmark-based healthcare company unveiled a set of new data that demonstrated ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/novo-nordisk-races-ahead-nysenvo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Theravance Milestone Payment (NASDAQ:THRX)</title>
		<link>http://www.straightstocks.com/stock-watch/theravance-milestone-payment-nasdaqthrx/</link>
		<comments>http://www.straightstocks.com/stock-watch/theravance-milestone-payment-nasdaqthrx/#comments</comments>
		<pubDate>Mon, 26 Oct 2009 13:45:36 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1494</guid>
		<description><![CDATA[Theravance, Inc. (NASDAQ:THRX) has announced that they have received a US$20 million milestone payment after their new drug telavancin was approved by the Food and Drug Administration panel. In September 2009, FDA approved the telavancin ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/theravance-milestone-payment-nasdaqthrx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alcon Takes Over Potentia (NYSE:ACL)</title>
		<link>http://www.straightstocks.com/stock-watch/alcon-takes-over-potentia-nyseacl/</link>
		<comments>http://www.straightstocks.com/stock-watch/alcon-takes-over-potentia-nyseacl/#comments</comments>
		<pubDate>Mon, 26 Oct 2009 13:00:16 +0000</pubDate>
		<dc:creator>Mike Brown</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1489</guid>
		<description><![CDATA[Alcon, Inc. (NYSE:ACL) has announced that they have inked a licensing and purchasing agreement with Potentia Pharmaceuticals. The eye drug company Alcon through the agreement has acquired the license to develop Potentia’s leading drug candidate, ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/alcon-takes-over-potentia-nyseacl/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amgen’s Plan for Denosumab (NASDAQ:AMGN)</title>
		<link>http://www.straightstocks.com/stock-watch/amgen%e2%80%99s-plan-for-denosumab-nasdaqamgn/</link>
		<comments>http://www.straightstocks.com/stock-watch/amgen%e2%80%99s-plan-for-denosumab-nasdaqamgn/#comments</comments>
		<pubDate>Fri, 23 Oct 2009 16:51:56 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1454</guid>
		<description><![CDATA[On Thursday, Amgen, Inc. (NASDAQ:AMGN) have opened up about the new plans about how the company will actually handle the request for the new information asked by the Food and Drug Administration panel. Many analysts ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/amgen%e2%80%99s-plan-for-denosumab-nasdaqamgn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>AstraZeneca and Bristol-Myers report mixed data (BMY, AZN)</title>
		<link>http://www.straightstocks.com/stock-watch/astrazeneca-and-bristol-myers-report-mixed-data-bmy-azn/</link>
		<comments>http://www.straightstocks.com/stock-watch/astrazeneca-and-bristol-myers-report-mixed-data-bmy-azn/#comments</comments>
		<pubDate>Thu, 22 Oct 2009 19:15:27 +0000</pubDate>
		<dc:creator>Brian Hill</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1392</guid>
		<description><![CDATA[   It was just three weeks ago when AstraZeneca and Bristol-Myers Squibb came up with an announcement that their new diabetes drug named Dapagliflozin has come up with positive results in the late-stage ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/astrazeneca-and-bristol-myers-report-mixed-data-bmy-azn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Antigenics’ shares slide down (NASDAQ:AGEN)</title>
		<link>http://www.straightstocks.com/stock-watch/antigenics%e2%80%99-shares-slide-down-nasdaqagen/</link>
		<comments>http://www.straightstocks.com/stock-watch/antigenics%e2%80%99-shares-slide-down-nasdaqagen/#comments</comments>
		<pubDate>Thu, 22 Oct 2009 18:40:53 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1396</guid>
		<description><![CDATA[   On Wednesday morning, Antigenics had a fresh round of bad news from European regulators announcing that they have rejected their new kidney cancer vaccine called Oncophage. The news soon showed its impact ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/antigenics%e2%80%99-shares-slide-down-nasdaqagen/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Wyeth Collaboration Problems (NYSE:PFE)</title>
		<link>http://www.straightstocks.com/stock-watch/pfizer-wyeth-collaboration-problems-nysepfe/</link>
		<comments>http://www.straightstocks.com/stock-watch/pfizer-wyeth-collaboration-problems-nysepfe/#comments</comments>
		<pubDate>Wed, 21 Oct 2009 15:00:17 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1381</guid>
		<description><![CDATA[   From the very first day when Pfizer and Wyeth announced their merger agreement, there has been a lot of commotion in the stock market at the same time concerns about how both ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/pfizer-wyeth-collaboration-problems-nysepfe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lupus Drug Data Fuels HGS (NASDAQ:HGSI)</title>
		<link>http://www.straightstocks.com/stock-watch/lupus-drug-data-fuels-hgs-nasdaqhgsi/</link>
		<comments>http://www.straightstocks.com/stock-watch/lupus-drug-data-fuels-hgs-nasdaqhgsi/#comments</comments>
		<pubDate>Wed, 21 Oct 2009 14:30:21 +0000</pubDate>
		<dc:creator>Sandra Kitchen</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1385</guid>
		<description><![CDATA[   Human Genome Sciences Inc made an announcement that their experimental lupus drug has shown positive results and works faster that what they had expected from the drug. Their new new named as ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/lupus-drug-data-fuels-hgs-nasdaqhgsi/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amgen faces FDA delays (NASDAQ:AMGN)</title>
		<link>http://www.straightstocks.com/stock-watch/amgen-faces-fda-delays-nasdaqamgn/</link>
		<comments>http://www.straightstocks.com/stock-watch/amgen-faces-fda-delays-nasdaqamgn/#comments</comments>
		<pubDate>Tue, 20 Oct 2009 15:00:22 +0000</pubDate>
		<dc:creator>Brian Hill</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1371</guid>
		<description><![CDATA[   On Monday morning Amgen Inc made an announcement that the Food and Drug Administration has issued them a Complete Response letter for the Biologic License Applications (BLA) for their new bone drug ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/amgen-faces-fda-delays-nasdaqamgn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA approves GSK’s Votrient (NYSE:GSK)</title>
		<link>http://www.straightstocks.com/stock-watch/fda-approves-gsk%e2%80%99s-votrient-nysegsk/</link>
		<comments>http://www.straightstocks.com/stock-watch/fda-approves-gsk%e2%80%99s-votrient-nysegsk/#comments</comments>
		<pubDate>Tue, 20 Oct 2009 14:00:51 +0000</pubDate>
		<dc:creator>Mike Brown</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1366</guid>
		<description><![CDATA[   It was a nice Monday morning for GSK when they made an announcement that the Food and Drug Administration has voted in the favor of their new cancer drug Votrient. The GSK ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/fda-approves-gsk%e2%80%99s-votrient-nysegsk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>AstraZeneca’s Crestor Approved (NYSE:AZN)</title>
		<link>http://www.straightstocks.com/stock-watch/astrazeneca%e2%80%99s-crestor-approved-nyseazn/</link>
		<comments>http://www.straightstocks.com/stock-watch/astrazeneca%e2%80%99s-crestor-approved-nyseazn/#comments</comments>
		<pubDate>Mon, 19 Oct 2009 14:00:55 +0000</pubDate>
		<dc:creator>Sandra Kitchen</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1356</guid>
		<description><![CDATA[   It was a good closing day for AstraZeneca as they announced that the Food and Drug Administration has approved Crestor (rosuvastatin calcium) for use in pediatric patients suffering from heterozygous familial hypercholesterolemia ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/astrazeneca%e2%80%99s-crestor-approved-nyseazn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Management Blamed (NYSE:PFE)</title>
		<link>http://www.straightstocks.com/stock-watch/pfizer-management-blamed-nysepfe/</link>
		<comments>http://www.straightstocks.com/stock-watch/pfizer-management-blamed-nysepfe/#comments</comments>
		<pubDate>Sat, 17 Oct 2009 22:22:06 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1352</guid>
		<description><![CDATA[   A subsidiary of Pfizer, Pharmacia and Upjohn has been sentenced after pleading guilty to illegally promoting Bextra pain killers. The company had promoted Bextra as a treatment for acute and surgical pain ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/pfizer-management-blamed-nysepfe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Wyeth acquisition could affect jobs (NYSE:PFE)</title>
		<link>http://www.straightstocks.com/stock-watch/pfizer-wyeth-acquisition-could-affect-jobs-nysepfe/</link>
		<comments>http://www.straightstocks.com/stock-watch/pfizer-wyeth-acquisition-could-affect-jobs-nysepfe/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 18:15:07 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1343</guid>
		<description><![CDATA[   On a Thursday morning, Pfizer announced that they have successfully completed the acquisition of Wyeth following the receipt of regulatory approval from all the government authorities required by the merger agreement and ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/pfizer-wyeth-acquisition-could-affect-jobs-nysepfe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Protalix Top Line Results (AMEX:PLX)</title>
		<link>http://www.straightstocks.com/stock-watch/protalix-top-line-results-amexplx/</link>
		<comments>http://www.straightstocks.com/stock-watch/protalix-top-line-results-amexplx/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 18:00:05 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1339</guid>
		<description><![CDATA[   On Thursday, shares of Protalix BioTherapeutics moved upwards after they announced the positive results from their Phase 3 clinical trial of UPLYSO drug for the treatment of Gaucher disease. The company announced ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/protalix-top-line-results-amexplx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amgen Facing Delays (NASDAQ:AMGN)</title>
		<link>http://www.straightstocks.com/stock-watch/amgen-facing-delays-nasdaqamgn/</link>
		<comments>http://www.straightstocks.com/stock-watch/amgen-facing-delays-nasdaqamgn/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 17:45:52 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1335</guid>
		<description><![CDATA[   Amgen Inc is not really sure if they will have to wait or not but many of the biotech investors have speculated that Amgen’s Bone drug may have to face significant delays ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/amgen-facing-delays-nasdaqamgn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OxiGENE’s New Merger (NASDAQ:OXGN)</title>
		<link>http://www.straightstocks.com/stock-watch/oxigene%e2%80%99s-new-merger-nasdaqoxgn/</link>
		<comments>http://www.straightstocks.com/stock-watch/oxigene%e2%80%99s-new-merger-nasdaqoxgn/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 17:25:49 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1331</guid>
		<description><![CDATA[   OxiGENE and VaxGen on Thursday morning announced that they have entered into a definitive merger agreement where OxiGENE will acquire VaxGen in exchange for common stock of OxiGENE Inc. The merger has ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/oxigene%e2%80%99s-new-merger-nasdaqoxgn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acorda Gains Momentum (NASDAQ:ACOR)</title>
		<link>http://www.straightstocks.com/stock-watch/acorda-gains-momentum-nasdaqacor/</link>
		<comments>http://www.straightstocks.com/stock-watch/acorda-gains-momentum-nasdaqacor/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 17:09:12 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1327</guid>
		<description><![CDATA[   Acorda Therapeutics had a not so very good Wednesday morning with NASDAQ halting their trading on the stock market as the review by the Food and Drug Administration panel was due. However, ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/acorda-gains-momentum-nasdaqacor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ziopharm Oncology Soars High (NASDAQ:ZIOP)</title>
		<link>http://www.straightstocks.com/stock-watch/ziopharm-oncology-soars-high-nasdaqziop/</link>
		<comments>http://www.straightstocks.com/stock-watch/ziopharm-oncology-soars-high-nasdaqziop/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 13:30:40 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1282</guid>
		<description><![CDATA[   On early Wednesday morning shares of Ziopharm Oncology moved up a whopping 37 percent after they announced the release of the promising data of their cancer drug Zymafos. The company said that ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/ziopharm-oncology-soars-high-nasdaqziop/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acorda Trading Halted (NASDAQ:ACOR)</title>
		<link>http://www.straightstocks.com/stock-watch/acorda-trading-halted-nasdaqacor/</link>
		<comments>http://www.straightstocks.com/stock-watch/acorda-trading-halted-nasdaqacor/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 13:00:37 +0000</pubDate>
		<dc:creator>Mike Brown</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1286</guid>
		<description><![CDATA[   It was not a good start for Acorda Therapeutics on Wednesday morning when NASDAQ decided to halt the trading of Acorda Therapeutics shares until the experts have voted on Acorda’s new MS ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/acorda-trading-halted-nasdaqacor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA approves Acorda’s MS drug (NASDAQ:ACOR)</title>
		<link>http://www.straightstocks.com/stock-watch/fda-approves-acorda%e2%80%99s-ms-drug-nasdaqacor/</link>
		<comments>http://www.straightstocks.com/stock-watch/fda-approves-acorda%e2%80%99s-ms-drug-nasdaqacor/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 12:30:32 +0000</pubDate>
		<dc:creator>Brian Hill</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1290</guid>
		<description><![CDATA[   It was a bad news for Acorda Therapeutics when they heard the news that NASDAQ has halted their trading and shares of Acorda Therapeutics were 18 percent down on the stock market. ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/fda-approves-acorda%e2%80%99s-ms-drug-nasdaqacor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Progenics-Wyeth Agreement (NASDAQ:PGNX)</title>
		<link>http://www.straightstocks.com/stock-watch/progenics-wyeth-agreement-nasdaqpgnx/</link>
		<comments>http://www.straightstocks.com/stock-watch/progenics-wyeth-agreement-nasdaqpgnx/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 12:00:29 +0000</pubDate>
		<dc:creator>Sandra Kitchen</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[advanced illness]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[constipation]]></category>
		<category><![CDATA[European Union]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Progenics Pharmaceuticals]]></category>
		<category><![CDATA[Relistor]]></category>
		<category><![CDATA[Relistor drug]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[USD]]></category>
		<category><![CDATA[Wyeth Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1294</guid>
		<description><![CDATA[   Progenics Pharmaceuticals have announced that they have entered an agreement with Wyeth Pharmaceuticals under which they will be regaining all the worldwide rights to the Relistor franchise from Wyeth Pharmaceuticals. Progenics had ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/progenics-wyeth-agreement-nasdaqpgnx/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Merck Galapagos Deal (NYSE:MRK)</title>
		<link>http://www.straightstocks.com/stock-watch/merck-galapagos-deal-nysemrk/</link>
		<comments>http://www.straightstocks.com/stock-watch/merck-galapagos-deal-nysemrk/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 11:30:27 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[atherosclerosis]]></category>
		<category><![CDATA[candidate for clinical development]]></category>
		<category><![CDATA[Crucell;]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[EUR]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Galapagos NV]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Metabolic Diseases]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[Tibotec]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1298</guid>
		<description><![CDATA[   Early Wednesday afternoon, Merck announced that they have made a decision of research collaboration with Galapagos NV. The news about the research collaboration had positive responses from analysts and the shares of ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/merck-galapagos-deal-nysemrk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NCOA Signs Sanofi-Aventis (NYSE:SNY)</title>
		<link>http://www.straightstocks.com/stock-watch/ncoa-signs-sanofi-aventis-nysesny/</link>
		<comments>http://www.straightstocks.com/stock-watch/ncoa-signs-sanofi-aventis-nysesny/#comments</comments>
		<pubDate>Fri, 16 Oct 2009 11:00:21 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[creative solutions]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Greg Irace]]></category>
		<category><![CDATA[healthcare needs]]></category>
		<category><![CDATA[healthcare organizations]]></category>
		<category><![CDATA[National Council On Aging]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[President and CEO]]></category>
		<category><![CDATA[Sanofi-Aventis U.S.]]></category>
		<category><![CDATA[Sanofi-Aventis;]]></category>
		<category><![CDATA[therapeutic solutions]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1302</guid>
		<description><![CDATA[   The NCOA (National Council On Aging) announced that they have added Sanofi-Aventis U.S. to their list of growing sponsors for BenefitsCheckUp program. NCOA has many companies and firms on the list of ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/ncoa-signs-sanofi-aventis-nysesny/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi-Aventis Deals with Dyax (NYSE:SNY)</title>
		<link>http://www.straightstocks.com/stock-watch/sanofi-aventis-deals-with-dyax-nysesny/</link>
		<comments>http://www.straightstocks.com/stock-watch/sanofi-aventis-deals-with-dyax-nysesny/#comments</comments>
		<pubDate>Thu, 15 Oct 2009 18:11:38 +0000</pubDate>
		<dc:creator>Sandra Kitchen</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Aventis]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Dyax]]></category>
		<category><![CDATA[FavStocks]]></category>
		<category><![CDATA[Fovea Pharmaceuticals]]></category>
		<category><![CDATA[Macular Edema]]></category>
		<category><![CDATA[Massachusetts]]></category>
		<category><![CDATA[Merrimack Pharmaceuticals]]></category>
		<category><![CDATA[pharmaceutical giant]]></category>
		<category><![CDATA[Retinal Vein Occlusion]]></category>
		<category><![CDATA[Sanofi;]]></category>
		<category><![CDATA[Treatment Of Cancer]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1261</guid>
		<description><![CDATA[   Sanofi-Aventis has recently been very close to MA-based Dyax. Recently Sanofi-Aventis had made an announcement that they have entered into an agreement with Fovea Pharmaceuticals for US$ 540 million to partner with ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/sanofi-aventis-deals-with-dyax-nysesny/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GlaxoSmithKline RNA Pact (NYSE:GSK)</title>
		<link>http://www.straightstocks.com/stock-watch/glaxosmithkline-rna-pact-nysegsk/</link>
		<comments>http://www.straightstocks.com/stock-watch/glaxosmithkline-rna-pact-nysegsk/#comments</comments>
		<pubDate>Wed, 14 Oct 2009 17:30:58 +0000</pubDate>
		<dc:creator>Brian Hill</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1253</guid>
		<description><![CDATA[   On early Monday morning GlaxoSmithKline has decided to pay upfront fees and milestone payments to the Dutch biotech company Prosensa. GSK has committed to pay the upfront fees of US$ 680 million ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/glaxosmithkline-rna-pact-nysegsk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vanda Inks Novartis Deal (NASDAQ:VNDA)</title>
		<link>http://www.straightstocks.com/stock-watch/vanda-inks-novartis-deal-nasdaqvnda/</link>
		<comments>http://www.straightstocks.com/stock-watch/vanda-inks-novartis-deal-nasdaqvnda/#comments</comments>
		<pubDate>Wed, 14 Oct 2009 17:00:14 +0000</pubDate>
		<dc:creator>Mike Brown</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1257</guid>
		<description><![CDATA[   On Monday morning, shares of Vanda Pharmaceuticals went up sharply after the announcement that they have inked a new licensing deal with Novartis that would earn them around US$ 465 million, of ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/vanda-inks-novartis-deal-nasdaqvnda/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi-Aventis’ Merial Expands (NYSE:SNY)</title>
		<link>http://www.straightstocks.com/stock-watch/sanofi-aventis%e2%80%99-merial-expands-nysesny/</link>
		<comments>http://www.straightstocks.com/stock-watch/sanofi-aventis%e2%80%99-merial-expands-nysesny/#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:15:10 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1265</guid>
		<description><![CDATA[   Sanofi-Aventis’ animal health group Merial has announced the new US$ 70 million project for the expansion of poultry-vaccines plant in the Nanchang development zone in China. Currently, Merial has been operating in ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/sanofi-aventis%e2%80%99-merial-expands-nysesny/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acorda shares sink (NASDAQ:ACOR)</title>
		<link>http://www.straightstocks.com/stock-watch/acorda-shares-sink-nasdaqacor/</link>
		<comments>http://www.straightstocks.com/stock-watch/acorda-shares-sink-nasdaqacor/#comments</comments>
		<pubDate>Mon, 12 Oct 2009 16:33:41 +0000</pubDate>
		<dc:creator>Brian Hill</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1204</guid>
		<description><![CDATA[   It was a not a good closing day for Acorda Therapeutics when shares of its company went down drastically after the negative review by the Food and Drug Administration panel. On Friday ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/acorda-shares-sink-nasdaqacor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Savient Pharma rises high (NASDAQ:SVNT)</title>
		<link>http://www.straightstocks.com/stock-watch/savient-pharma-rises-high-nasdaqsvnt/</link>
		<comments>http://www.straightstocks.com/stock-watch/savient-pharma-rises-high-nasdaqsvnt/#comments</comments>
		<pubDate>Mon, 12 Oct 2009 15:30:41 +0000</pubDate>
		<dc:creator>Sandra Kitchen</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1207</guid>
		<description><![CDATA[   On a late Friday afternoon, shares of Savient Pharmaceuticals bounced back as analysts for Oppenheimer and Co. raised his views on Savient Pharmaceuticals and its new chronic gout drug candidate Krystexxa. The ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/savient-pharma-rises-high-nasdaqsvnt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Johnson  Johnson gearing up (NYSE:JNJ)</title>
		<link>http://www.straightstocks.com/stock-watch/johnson-johnson-gearing-up-nysejnj/</link>
		<comments>http://www.straightstocks.com/stock-watch/johnson-johnson-gearing-up-nysejnj/#comments</comments>
		<pubDate>Mon, 12 Oct 2009 15:00:47 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1211</guid>
		<description><![CDATA[   The world’s biggest healthcare company, Johnson &#38; Johnson has stated that currently they are waiting for the approval of their new products. On a Tuesday morning, the world’s premier health company provided ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/johnson-johnson-gearing-up-nysejnj/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer gets another setback (NYSE:PFE)</title>
		<link>http://www.straightstocks.com/stock-watch/pfizer-gets-another-setback-nysepfe/</link>
		<comments>http://www.straightstocks.com/stock-watch/pfizer-gets-another-setback-nysepfe/#comments</comments>
		<pubDate>Mon, 12 Oct 2009 14:30:26 +0000</pubDate>
		<dc:creator>Mike Brown</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1215</guid>
		<description><![CDATA[   Pfizer Inc announced one of the most shocking news on Friday that the conclusions of their experimental lung cancer drug were not definitive. The news was announced on a Friday afternoon after ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/pfizer-gets-another-setback-nysepfe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mixed results from Avanir (NASDAQ:AVNR)</title>
		<link>http://www.straightstocks.com/stock-watch/mixed-results-from-avanir-nasdaqavnr/</link>
		<comments>http://www.straightstocks.com/stock-watch/mixed-results-from-avanir-nasdaqavnr/#comments</comments>
		<pubDate>Mon, 12 Oct 2009 14:00:59 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1219</guid>
		<description><![CDATA[   Avanir Pharmaceuticals on Friday announced that the test results for their drug candidate Zenvia shows mixed results for the treatment of involuntary emotional outbursts in patients with multiple sclerosis. Avanir Pharmaceuticals is ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/mixed-results-from-avanir-nasdaqavnr/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Targacept Public Offering (NASDAQ:TRGT)</title>
		<link>http://www.straightstocks.com/stock-watch/targacept-public-offering-nasdaqtrgt/</link>
		<comments>http://www.straightstocks.com/stock-watch/targacept-public-offering-nasdaqtrgt/#comments</comments>
		<pubDate>Fri, 09 Oct 2009 17:30:13 +0000</pubDate>
		<dc:creator>Jyotsna Ramani</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[FavStocks]]></category>

		<guid isPermaLink="false">http://www.favstocks.com/?p=1160</guid>
		<description><![CDATA[   In the early morning trade on Thursday, Targacept Inc, a biotechnology company has announced that it is publicly offering 2.2 million shares of common stock. Though the company has not yet priced ...]]></description>
		<wfw:commentRss>http://www.straightstocks.com/stock-watch/targacept-public-offering-nasdaqtrgt/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How to Profit from Immunotherapy  Regenerative Medicine</title>
		<link>http://www.straightstocks.com/investing-lessons/how-to-profit-from-immunotherapy-regenerative-medicine/</link>
		<comments>http://www.straightstocks.com/investing-lessons/how-to-profit-from-immunotherapy-regenerative-medicine/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 17:30:47 +0000</pubDate>
		<dc:creator>Contrarian Profits</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Investing Lessons]]></category>
		<category><![CDATA[Market Commentary]]></category>
		<category><![CDATA[Allergy]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[Bristol]]></category>
		<category><![CDATA[Bristol Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[contrarian profits]]></category>
		<category><![CDATA[Erbitux]]></category>
		<category><![CDATA[greater technology]]></category>
		<category><![CDATA[Herceptin;]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Marc Lichtenfeld;]]></category>
		<category><![CDATA[regenerative medicine]]></category>
		<category><![CDATA[specific  infectious]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.contrarianprofits.com/?p=20884</guid>
		<description><![CDATA[pThe procedure has been called “one of the most barbaric mistakes ever perpetrated by mainstream medicine.” Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe./p
pThis was the early method of performing a lobotomy. And just 50 years ago, they were carried out not only on severely mentally ill people, but also on moody teenagers, or housewives who’d lost their enthusiasm for domestic work. Seriously. Over 40,000 Americans were lobotomized, often with catastrophic results./p
pThankfully, they’re a thing of the past. But it made me think about how medicine has changed over the years and what practices were once acceptable.#8230;/p]]></description>
		<wfw:commentRss>http://www.straightstocks.com/investing-lessons/how-to-profit-from-immunotherapy-regenerative-medicine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
